Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

A newly developed nomogram predicts preoperative microvascular invasion in patients with HCC, improving surgical planning and outcomes.

(NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the ...

Hepatic resection and transplantation remain the standard curative therapies for hepatocellular carcinoma ... liver disease are best served by transplant evaluation; however, the best treatment ...

liver transplant is the treatment of choice Nonsurgical treatments (PEI, RFA, and TACE) are employed to minimize drop-out from the transplant waiting list, which nevertheless occurs in 20% of ...

The then 36-year-old courtroom bailiff received Milwaukee County General Hospital's 500th kidney transplant. After suffering from a kidney infection for a decade and spending months on dialysis ...

This case report details a patient with hepatocellular carcinoma who developed T1DM and DKA following ... his admission to the Department of Hepatobiliary, Pancreatic, and Transplant Surgery at Xi’an ...

Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US). Patterns of ...

Rates and risk factors for recurrence of hepatocellular carcinoma after initial complete remission in response to transcatheter arterial chemoembolization: A systematic review and meta-analysis. This ...